Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 40,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total value of $158,400.00. Following the completion of the transaction, the director directly owned 6,218,287 shares of the company’s stock, valued at $24,624,416.52. This trade represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, June 2nd, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.68, for a total transaction of $110,400.00.
• On Tuesday, May 5th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.52, for a total transaction of $105,600.00.

Recursion Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ:RXRX traded up $0.04 during trading on Thursday, hitting $3.76. 22,268,404 shares of the company were exchanged, compared to its average volume of 18,288,820. The stock has a market capitalization of $1.99 billion, a P/E ratio of -3.13 and a beta of 1.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.77 and a 12-month high of $7.18. The firm’s 50 day moving average price is $3.33 and its 200-day moving average price is $3.65.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08. The business had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The company’s revenue for the quarter was down 56.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.50) EPS. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RXRX has been the topic of several research reports. Wall Street Zen lowered Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. JPMorgan Chase & Co. dropped their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Morgan Stanley lifted their price target on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $8.10.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. NewEdge Advisors LLC increased its position in Recursion Pharmaceuticals by 28.1% during the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock worth $56,000 after purchasing an additional 2,428 shares in the last quarter. Equitable Holdings Inc. lifted its holdings in Recursion Pharmaceuticals by 7.1% in the 3rd quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock valued at $192,000 after purchasing an additional 2,600 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Recursion Pharmaceuticals by 1.2% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 232,370 shares of the company’s stock worth $954,000 after purchasing an additional 2,753 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 29.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,706 shares of the company’s stock worth $64,000 after buying an additional 2,883 shares in the last quarter. Finally, Ascent Wealth Partners LLC grew its holdings in shares of Recursion Pharmaceuticals by 11.8% during the first quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company’s stock worth $86,000 after buying an additional 2,974 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.